9-nitrocamptothecin 20(S)-O-acetate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: 9-nitrocamptothecin 20(S)-O-acetate
• 英文别名: 9-nitrocamptothecin-20-O-acetate；[(19S)-19-ethyl-8-nitro-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] acetate
• 化学式: C₂₂H₁₇N₃O₇
• 分子量: 435.393
• InChiKey: IPMPMVKUDVDNOL-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  132
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  9-nitrocamptothecin 20(S)-O-acetate 以47的产率得到(10-chloro-19-ethyl-8-nitro-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl) acetate
  参考文献：
  名称：

  Bioorganic amp; Medicinal Chemistry Letters 2009, 19, 2018-2021

  摘要：

  DOI：
• 作为产物：
  描述：

  乙酸酐 、 鲁比替康 在 吡啶 作用下， 反应 24.0h， 以45%的产率得到9-nitrocamptothecin 20(S)-O-acetate
  参考文献：
  名称：

  Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs

  摘要：

  通用公式所代表的紫杉醇衍生物如下所述： 其中当R1为H时，R为C2-C4烷基、C6-C15烷基、C3-C8环烷基、C2-C15烯基或C2-C15环氧基；当R2为硝基或氨基时，R1为C1-C15烷基、C1-C15烯基、C3-C8环烷基或环氧基。还描述了包括这些特定紫杉醇衍生物的脂质体前药，其受限于脂质体传递系统。还公开了制备这些前药以及在癌症治疗中使用它们的方法。

  公开号：

  US06352996B1

文献信息

• Novel hexacyclic compounds
  申请人：——

  公开号：US20030144304A1

  公开（公告）日：2003-07-31

  The present invention relates to hexacyclic compound of the formula [1], 1 wherein Z, R 3 and R 4 are as identified therein, and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of cell proliferative disorders.

  本发明涉及公式［1］中的六环化合物，其中Z、R3和R4如所述，以及其药用可接受的盐。这些化合物可用于治疗细胞增殖性疾病。
• Method for identifying an enzyme to design anti-cancer compounds
  申请人：——

  公开号：US20030138864A1

  公开（公告）日：2003-07-24

  The present invention relates to a method for identification of enzymes that are preferentially expressed in certain tumor tissue as compared with rapidly growing normal cells or tissue, use of said enzymes for the compound design to generate an active anti-cancer substance selectively in tumor tissue, compounds designed based on said enzymes, their pharmaceutically acceptable salts as well as pharmaceutical composition thereof.

  本发明涉及一种酶的鉴定方法，该酶在某些肿瘤组织中与快速生长的正常细胞或组织相比表达优势，利用该酶设计化合物以在肿瘤组织中选择性地生成活性抗癌物质，基于该酶设计的化合物、其药学上可接受的盐以及药物组成物。
• Synthesis of new camptothecin analogs with improved antitumor activities
  作者：Satoshi Niizuma、Masao Tsukazaki、Hitomi Suda、Takeshi Murata、Jun Ohwada、Sawako Ozawa、Hiroshi Fukuda、Chikako Murasaki、Masami Kohchi、Kenji Morikami、Kiyoshi Yoshinari、Mika Endo、Masako Ura、Hiromi Tanimura、Yoko Miyazaki、Tsuyoshi Takasuka、Akira Kawashima、Eitaro Nanba、Kounosuke Nakano、Kotaro Ogawa、Kazuko Kobayashi、Hisafumi Okabe、Isao Umeda、Nobuo Shimma

  DOI：10.1016/j.bmcl.2009.02.031

  日期：2009.4

  hexacyclic camptothecin analogs containing cyclic amidine, urea, or thiourea moiety were designed and synthesized based on the proposed 3D-structure of the topoisomerase I (Topo I)/DNA/camptothecin ternary complex. The analogs were prepared from 9-nitrocamptothecin via 7,9-diaminocamptothecin derivatives as a key intermediate. Among them, 7c exhibited in vivo antitumor activities superior to CPT-11 in

  基于拓扑异构酶I（Topo I）/ DNA /喜树碱三元复合物的3D结构，设计并合成了含有环am，尿素或硫脲部分的新型六环喜树碱类似物。由9-硝基喜树碱经7，9-二氨基喜树碱衍生物作为关键中间体制备类似物。其中，7c在人类癌症异种移植模型中以最大耐受剂量表现出优于CPT-11的体内抗肿瘤活性，尽管其在体外的抗增殖活性可与SN-38媲美。
• Alkyl Esters of Camptothecin and 9-Nitrocamptothecin:  Synthesis, in Vitro Pharmacokinetics, Toxicity, and Antitumor Activity
  作者：Zhisong Cao、Nick Harris、Anthony Kozielski、Dana Vardeman、John S. Stehlin、Beppino Giovanella

  DOI：10.1021/jm9607562

  日期：1998.1.1

  Eleven camptothecin esters, 6a-e and 7a-f, were prepared by straightforward acylation of camptothecins with the corresponding acylating reagents such as organic anhydrides and carboxylic acid chlorides. The in vitro pharmacokinetic determination of lactone levels of esters 6a and 7b showed that the biological life span of their lactone forms in human and mouse plasma significantly increased when compared with their mother compounds, camptothecin (3) and 9-nitrocamptothecin (4). The differences of lactone levels between human plasma and mouse plasma for 6a and 7b were much smaller than what was observed for their mother compounds. The in vivo antitumor activity and toxicity studies demonstrated that some of these esters were very active against human tumor xenografts in nude mice and had an exceptional lack of toxicity in nude mice, even at enormous doses.
• CONDENSED CAMPTOTHECINS AS ANTITUMOR AGENTS
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1480984A2

  公开（公告）日：2004-12-01